



TEL : 0091- 217 - 2310824
: 0091- 217 - 2451500
FAX : 0091- 217 - 2451521
E-MAIL : info@balajiamines.com
WEBSITE : http://www.balajiamines.com

Balaji



ISO 45001:2018
ISO 14001:2015
ISO 9001:2015
www.tuv.com
ID 9105038797



CIN : L24132MH1988PLC049387

AMINES LIMITED
... A Speciality Chemical Company

Regd. Off. : 'Balaji Towers' No. 9/1A /1,
Hotgi Road, Aasara Chowk, Solapur - 413 224,
Maharashtra. (India)

14th May, 2026

To,
The General Manager-Department of
Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

The Manager-Listing Department,
National Stock Exchange of India Limited,
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Code : 530999

Symbol : BALAMINES

Dear Sir/Madam,

Sub.: Press Release in connection with Audited Financial Results for the Quarter and Year ended 31st March, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please enclosed herewith a copy of Press Release in connection with the Audited Financial Results for the Quarter and Year ended 31st March, 2026.

The aforesaid information is also being made available on the website of the Company at <https://www.balajiamines.com/investor-relations.php>.

This is for your information and records.

Thanking you.

Yours faithfully,

For Balaji Amines Limited

Abhijeet Kothadiya
Company Secretary & Compliance Officer

Encl.: a/a

Investor Release

For Immediate Release

Consolidated Q4FY26 Revenue stood at ₹ 403 Crore;

EBITDA stood at ₹ 102 Crore;

Net Profit stood at ₹ 65 Crore

Solapur, May 13, 2026: Balaji Amines Limited (“Company”), a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, announced its audited financial results for the financial year ended March 31st, 2026.

Key Financial Highlights are as follows:

(Rupees in Cr except otherwise stated)

Particulars	Standalone		Consolidated		Standalone		Consolidated	
	Q4FY26	Q4FY25	Q4FY26	Q4FY25	FY26	FY25	FY26	FY25
Total Income	370	327	403	361	1,320	1,296	1,454	1,430
EBITDA	94	64	102	68	275	249	294	265
EBITDA Margin (%)	26%	20%	25%	19%	21%	19%	20%	19%
PAT	62	40	65	40	166	156	169	159
PAT Margin (%)	17%	12%	16%	11%	13%	12%	12%	11%
Cash PAT*	75	51	81	54	226	204	241	218
Cash PAT Margin (%)	20%	16%	20%	15%	17%	16%	17%	15%
Sales Volume (in MT)	25,394	24,047	27,341	25,872	98,622	98,086	1,06,970	1,04,393

*Cash PAT is PAT + Depreciation + Deferred tax

Consolidated Performance Highlights for Q4 & FY26

Revenue from Operations for Q4FY26 stood at ₹ 403 crore, as compared to ₹ 361 crore in Q3FY26, indicating a stable operational performance which is around 12%. The Sales Volumes were maintained at similar levels to the previous period. The increase in revenue is due to commodity prices and consistent demand across key segments.

Total volumes stood at 27,341 MT for Q4 FY26 as against 25,871 MT in Q4 FY25.

For Q4FY26,

- Amines volumes stood at 7,746 MT
- Amines Derivatives volumes stood at 8,935 MT
- Specialty Chemicals volumes stood at 10,660 MT

EBITDA for Q4FY26 was ₹ 102 crore, as compared to ₹ 62 crore in Q3FY26 and ₹ 68 crore in Q4FY25.

EBITDA margin for Q4FY26 stood at 25% as against 18% in Q3FY26 and 19% in Q4FY25.

PAT for Q4FY26 was ₹ 65 crore as compared to ₹ 31 crore in Q3FY26. **Diluted EPS** for Q4FY26 stood at ₹ 19.99 per equity share as against ₹ 9.49 in Q3FY26.

On a standalone basis, we are a zero-debt company.

Update on New Projects Commissioned and New Proposed Products/Projects

- **DME Plant at Unit-IV.** The Plant is expected to be commissioned during the First Quarter of FY 2026-27. This has an application in the Aerosol industry apart from using it as a replacement to LPG for Industrial and Commercial usage.
- **N-Methyl Morpholine (NMM)** - 5000 TPA is under execution and expected to be commissioned during the FY 2026-27
- **Acetonitrile:** Improved process based ACN plant is under execution, the same is expected to be commissioned during the Second Quarter of FY 2026-27.

All the above projects would be completed as planned with internal accruals.

New expansion of Rs. 750 crs in Subsidiary Balaji Speciality Chemicals Limited

Investment is being made for wide range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30%(Solution), Sodium Cyanide (NaCN) 100%(Pellets), Ethylene Diamine Tetra Acetic Acid (EDTA), Ethylene Diamine Tetra Acetic Acid Disodium Salts (EDTA-2Na) etc.,

The Industries, Energy, and Labour Department, Government of Maharashtra, has granted Mega Project status to our Expansion Project for Balaji Speciality Chemicals under the Packaged Scheme of Incentives (PSI), 2019, with a proposed investment of Rs. 750 Crores in a phased manner.

At Unit-I, a brown field project for EDA based products with an additional reactor to manufacture value added products such, DETA, TETA, PIP, AEEA, AEP etc., is expected to be commissioned during first half of FY 2026-27.

At Unit-II (The Greenfield Project at MIDC, Chincholi), works of erection and installation of equipment is in progress. The proposed project is for manufacture of HCN, NaCN, EDTA and EDTA-2Na. The same are expected to be commissioned during the Q4 of FY 2026-27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented,

For the quarter and year ended 31st March 2026, the Company demonstrated resilience in its operating performance despite a temporary external disruption during the month of March 2026. Production was briefly affected due to geopolitical situation; however, the Company was able to mitigate the impact through prudent inventory planning and uninterrupted availability of raw material. This has contributed to the Company maintain supplies and ensure that plant operations remained stable.

The 4th quarter performance has strengthened the Company's integrated manufacturing model and execution capabilities, which enabled it to mitigate near-term volatility without materially affecting operations and customer servicing. While demand conditions across certain end-user industries remained stable, the Company's established amines, its derivatives and specialty chemicals business continued to provide a stable operation.

Balaji Amines also continued to make progress on its strategic priorities during the quarter. The ramp-up of electronic-grade DMC, DMF and other products is steadily strengthening the Company's presence in higher-value segments and remains an important part of its growth agenda.

As the Company enters the new financial year, its focus remains on improving utilization across all the plants, enhancing operating leverage and maintaining disciplined execution. Backed by a resilient business plan and growing specialty chemicals portfolio and

emerging export opportunities, Balaji Amines remains well placed for gradual ramping up of operations over the period.

About Balaji Amines Limited (BAL)

Balaji Amines Ltd (BAL), set up in 1988, is a leading manufacturer of Aliphatic Amines in India. Broadly, the company is specialised in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Aliphatic Amines and Specialty Chemicals. Its business is broadly classified into three segments - Amines, Specialty Chemicals and Derivatives. BAL commenced manufacturing of Methyl Amines in 1990, and later added facilities of Ethyl Amines and other derivatives of Methyl amines and Ethyl amines. The company enjoys leadership position in many of its products like Monomethylamine (MMA), Dimethyl amine (DMA), Trimethylamine (TMA), Dimethyl Amino Ethanol (DMAE), Mono Methyl Amino Ethanol etc.

It caters to a host of industries like Pharma, Agro Chemicals, Paint Stripping & Resins, Rubber cleaning chemicals etc. The company has four state of the art manufacturing sites – three near Solapur and one near Hyderabad. In addition, BAL possesses a fully furnished Laboratory which helps the company in development of newer products. A majority of its products are being exported to major customers worldwide and the company has become one of the leaders in Specialty Chemicals among the International Specialty Chemical players. The company also operates a 5-star hotel in Solapur – Balaji Sarovar. It has tied up with Sarovar group for management of this hotel.

For more information, please visit www.balajiamines.com

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Company	Investor Relations Advisors
<p>Balaji Amines Limited</p> <p>CIN No: L24132MH1988PLC049387</p> <p>Email id: cs@balajiamines.com</p>	<p>MUFG Intime India Private Limited</p> <p>Mr. Nikunj Seth: +91 9773397958 nikunj.seth@in.mpms.mufg.com</p> <p>Ms. Sejal Bhattar: +91 7666736666 sejal.bhattar@in.mpms.mufg.com</p>
